The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-09), Aytu BioPharma's share price is $3.21. Aytu BioPharma's Book Value per Share for the quarter that ended in Dec. 2023 was $5.90. Hence, Aytu BioPharma's PB Ratio of today is 0.54.
The historical rank and industry rank for Aytu BioPharma's PB Ratio or its related term are showing as below:
AYTU'
s PB Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.78 Max: 9.36
Current: 0.54
During the past 13 years, Aytu BioPharma's highest PB Ratio was 9.36. The lowest was 0.14. And the median was 0.78.
AYTU's PB Ratio is ranked better than 92.98% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs AYTU: 0.54
During the past 12 months, Aytu BioPharma's average Book Value Per Share Growth Rate was -56.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -63.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -58.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Aytu BioPharma was -34.30% per year. The lowest was -80.10% per year. And the median was -61.65% per year.
Back to Basics: PB Ratio
Aytu BioPharma PB Ratio Historical Data
The historical data trend for Aytu BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's PB Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's PB Ratio falls into.
Aytu BioPharma PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Aytu BioPharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aytu BioPharma PB Ratio Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma (Aytu BioPharma) Business Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AYTU has been successfully added to your 